Cantor Fitzgerald Reaffirms Overweight Rating for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $67.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 149.91% from the stock’s current price.

Several other brokerages also recently issued reports on CLDX. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They set a “neutral” rating and a $45.00 price objective for the company. Citigroup initiated coverage on Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, December 19th. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $26.81 on Thursday. The stock has a 50 day simple moving average of $26.12 and a 200 day simple moving average of $32.70. Celldex Therapeutics has a 52-week low of $22.93 and a 52-week high of $53.18. The firm has a market capitalization of $1.78 billion, a PE ratio of -10.43 and a beta of 1.57.

Insider Buying and Selling

In other news, CEO Anthony S. Marucci bought 11,500 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the purchase, the chief executive officer now owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 3.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Celldex Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its holdings in Celldex Therapeutics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock valued at $601,000 after purchasing an additional 325 shares during the last quarter. KBC Group NV lifted its stake in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 495 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in shares of Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 638 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Celldex Therapeutics by 23.7% during the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 1,504 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Celldex Therapeutics in the 2nd quarter valued at about $76,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.